CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Entry into a Material Definitive Agreement

CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

On December 20, 2017, CASI Pharmaceuticals, Inc. (the “Company”) entered into a Third Amendment to Secured Promissory Note (the “Third Amendment”) with Talon Therapeutics, Inc. (“Talon”), an affiliate of Spectrum Pharmaceuticals, Inc.

As previously reported, the Company delivered to Talon a $1.5 million Secured Promissory Note on September 17, 2014 (the “Note”), and amended on September 28, 2015 (the “First Amendment”) and December 13, 2016 (the “Second Amendment”), in connection with the exclusive license to the commercial oncology drug, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) in greater China.

The Note had a maturity date of March 17, 2016. to the First Amendment, the Company and Talon agreed to change the maturity date of the Note to March 17, 2017. to the Second Amendment, the Company and Talon agreed to change the maturity date of the Note to March 17, 2018. to the Third Amendment, the Company and Talon agreed to change the maturity date of the Note to September 17, 2019. All other terms remain the same. A copy of the Third Amendment is filed as Exhibit 4.4 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit Number Description
4.1 Secured Promissory Note, dated as of September 17, 2014, issued to Talon Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed on September 19, 2014)
4.2 First Amendment to Secured Promissory Note, dated as of September 28, 2015, by and between the Company and Talon Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed on October 1, 2015.
4.3 Second Amendment to Secured Promissory Note, dated as of December 13, 2016, by and between the Company and Talon Therapeutics, Inc. (incorporated by reference to Exhibit 4.3 of the Company’s Current Report on Form 8-K filed on December 16, 2016.
4.4 Third Amendment to Secured Promissory Note, dated as of December 20, 2017, by and between the Company and Talon Therapeutics, Inc. (filed herewith)


CASI Pharmaceuticals, Inc. Exhibit
EX-4.4 2 tv481895_ex4-4.htm EXHIBIT 4.4   Exhibit 4.4   THIRD AMENDMENT TO SECURED PROMISSORY NOTE   This Third Amendment to Secured Promissory Note (“Amendment”) is made and entered into as of December 20,…
To view the full exhibit click here

About CASI PHARMACEUTICALS, INC. (NASDAQ:CASI)

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

An ad to help with our costs